about
Bioengineering Lantibiotics for Therapeutic SuccessNew horizons for host defense peptides and lantibioticsSite-directed mutations in the lanthipeptide mutacin 1140.Streptococcal bacteriocins and the case for Streptococcus salivarius as model oral probiotics.Cerecidins, novel lantibiotics from Bacillus cereus with potent antimicrobial activityAnti-infective properties of bacteriocins: an update.Novel avenues for Clostridium difficile infection drug discovery.Advances in the arsenal of tools available enabling the discovery of novel lantibiotics with therapeutic potential.Multipronged approach for engineering novel peptide analogues of existing lantibiotics.Antibacterial Peptides: Opportunities for the Prevention and Treatment of Dental Caries.Genome database mining for the discovery of novel lantibiotics.Targeting bactoprenol-coupled cell envelope precursors.Pharmacological and pharmacokinetic properties of lanthipeptides undergoing clinical studies.The leader peptide of mutacin 1140 has distinct structural components compared to related class I lantibiotics.Mechanistic Understanding of Lanthipeptide Biosynthetic Enzymes.Advances in Development of Antimicrobial Peptidomimetics as Potential Drugs.Biosynthesis and transport of the lantibiotic mutacin 1140 produced by Streptococcus mutans.Improving the attrition rate of Lanthipeptide discovery for commercial applications.Carboxyl Analogue of Mutacin 1140, a Scaffold for Lead Antibacterial Discovery.Evaluating the feasibility of lantibiotics as an alternative therapy against bacterial infections in humans.Mutacin 1140 Lantibiotic Variants Are Efficacious Against Clostridium difficile Infection.Covalent Structure and Bioactivity of the Type AII Lantibiotic Salivaricin A2.Perspectives on lantibiotic discovery - where have we failed and what improvements are required?OG716: Designing a fit-for-purpose lantibiotic for the treatment of Clostridium difficile infections.
P2860
Q26774123-BA526F53-F522-44A0-8DCF-9F86E960842EQ26997072-6EB28466-D00B-4FC5-96EC-2C38DB8156B6Q34679435-96053AF3-148B-4CE1-8622-53BEFF72C838Q37590315-E7D9A9B4-C6EF-4163-A461-D93186E9250BQ37712931-D03AB11B-BEC4-44B3-A02C-0827C1FB3BC2Q38056436-CC571B0E-2D1F-42F3-8475-A2987FCE8378Q38083297-0C29B87E-2C52-4322-962C-A7FA2426D35AQ38177305-EEE07F5F-3A71-45DC-9DAD-7F70D2C90386Q38500614-95A9D009-491A-438C-BABC-2B8CED71160DQ38701785-8F769405-95E7-4B81-B685-7FD6852DA14AQ38901217-EB95FE07-97ED-4E68-A994-88B43F5D0BC0Q38919751-E9D29D72-C875-41EF-9CA2-E5525A6872A0Q39065285-AA574299-719D-40CE-A19C-FCCEB4A3B8ECQ39097534-9F7464EC-4F1D-4558-95B6-76A059B07FD6Q39109460-EA7BA4FC-99F0-43FB-A01F-2DCAFB1A375AQ40076286-1BC1343A-9B44-4559-9D35-BE0939D0C832Q41553325-2DA78F71-F217-4340-888F-8F0049D389F3Q47383314-8A98A2C9-F1DC-4A9C-AB8E-1E2DA5EA31A6Q51005035-F8A93CD7-30F4-4DA4-AEB3-9BF5EEF8EF2BQ51712533-DC2457C0-E30E-4C2F-8D23-53AEA50063FFQ52608578-5C293720-2E72-4FA6-8FA6-61894F607109Q52739856-E2521EAF-7B24-4F01-8688-E2BEFCE37287Q53603656-C77FD711-0497-49A9-9BCD-21AACBB9C54EQ55307893-6E43694A-2734-47A6-808C-6BED416288ED
P2860
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Pharmacodynamic activity of the lantibiotic MU1140.
@en
Pharmacodynamic activity of the lantibiotic MU1140.
@nl
type
label
Pharmacodynamic activity of the lantibiotic MU1140.
@en
Pharmacodynamic activity of the lantibiotic MU1140.
@nl
prefLabel
Pharmacodynamic activity of the lantibiotic MU1140.
@en
Pharmacodynamic activity of the lantibiotic MU1140.
@nl
P2093
P2860
P1476
Pharmacodynamic activity of the lantibiotic MU1140.
@en
P2093
Hartmut Derendorf
Jeffery D Hillman
Oliver G Ghobrial
P2860
P356
10.1016/J.IJANTIMICAG.2008.07.028
P577
2008-10-02T00:00:00Z